Paroxetine
Product Images NDC 63629-9500

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Paroxetine (NDC 63629-9500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636299500)

Label for Paroxetine Extended-Release Tablets, USP, 37.5 mg, from Bryant Ranch Prepack. The label states the product NDC 63629-9500-01 and package size of 30 tablets. It includes storage instructions, a pharmacist note on dispensing, and dosage information. The label features the BRP Pharmaceuticals logo and barcode.*

FDA Label Image

Chemical Structure (Paroxetine 01)

Chemical structure diagram of paroxetine hydrochloride, showing its fluorophenyl group, piperidine ring, and dioxolane ring components.*

FDA Label Image

Figure 1 (Paroxetine 02)

A forest plot chart showing fold changes and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for several drugs interacting with paroxetine. The drugs listed include Pimozide 2 mg, Desipramine 100 mg, Propranolol 80 mg twice daily, Digoxin 0.25 mg once daily, and Phenytoin 300 mg. The x-axis represents change relative to reference on a logarithmic scale from 0.1 to 10.0.*

FDA Label Image

Figure 2 (Paroxetine 03)

A forest plot chart showing the fold change and 90% confidence interval of pharmacokinetic parameters (Cmax and AUC) of Paroxetine when interacting with various drugs: Cimetidine 300 mg thrice daily, Phenobarbital 100 mg once daily, Phenytoin 300 mg once daily, Digoxin 0.25 mg once daily, and Diazepam 5 mg thrice daily. The x-axis represents change relative to reference from 0 to 2.*

FDA Label Image

Figure 3 (Paroxetine 04)

A chart titled 'Population description' comparing pharmacokinetic parameters (Cmax, Cmin, and AUC) across different populations, including renal impairment (mild, moderate, severe), hepatic impairment, age groups (>65 years with doses 20, 30, and 40 mg once daily), and gender (males). The chart shows fold change and 90% confidence intervals relative to reference values on a logarithmic scale ranging from 0.5 to 50.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.